Analysts expect that Aimmune Therapeutics, Inc. (NASDAQ:AIMT) will report earnings of ($0.70) per share for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Aimmune Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.84) and the highest estimate coming in at ($0.63). Aimmune Therapeutics posted earnings per share of ($0.55) in the same quarter last year, which suggests a negative year over year growth rate of 27.3%. The firm is scheduled to report its next earnings results on Wednesday, March 21st.

On average, analysts expect that Aimmune Therapeutics will report full year earnings of ($2.52) per share for the current year, with EPS estimates ranging from ($2.63) to ($2.45). For the next fiscal year, analysts expect that the firm will post earnings of ($3.04) per share, with EPS estimates ranging from ($3.55) to ($2.33). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that cover Aimmune Therapeutics.

Aimmune Therapeutics (NASDAQ:AIMT) last released its earnings results on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.09.

Several equities analysts have recently issued reports on the company. Cantor Fitzgerald assumed coverage on Aimmune Therapeutics in a report on Tuesday. They issued an “overweight” rating for the company. BidaskClub lowered Aimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday. Zacks Investment Research lowered Aimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, December 6th. ValuEngine lowered Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Finally, Wedbush reissued an “outperform” rating and set a $70.00 price objective on shares of Aimmune Therapeutics in a report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. Aimmune Therapeutics presently has an average rating of “Buy” and a consensus price target of $53.80.

Aimmune Therapeutics (NASDAQ AIMT) opened at $33.60 on Wednesday. Aimmune Therapeutics has a twelve month low of $15.97 and a twelve month high of $38.86.

In other Aimmune Therapeutics news, insider Douglas T. Sheehy sold 47,425 shares of the stock in a transaction on Monday, October 23rd. The stock was sold at an average price of $34.44, for a total transaction of $1,633,317.00. Following the sale, the insider now owns 34,300 shares in the company, valued at $1,181,292. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Stephen George Dilly sold 100,000 shares of the stock in a transaction on Monday, September 25th. The stock was sold at an average price of $25.01, for a total value of $2,501,000.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 274,986 shares of company stock valued at $7,533,100. 17.59% of the stock is owned by corporate insiders.

Several large investors have recently bought and sold shares of AIMT. Teachers Advisors LLC lifted its position in shares of Aimmune Therapeutics by 2.6% during the first quarter. Teachers Advisors LLC now owns 44,349 shares of the biotechnology company’s stock worth $964,000 after acquiring an additional 1,120 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Aimmune Therapeutics by 5.3% during the first quarter. Geode Capital Management LLC now owns 207,210 shares of the biotechnology company’s stock worth $4,502,000 after acquiring an additional 10,461 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in shares of Aimmune Therapeutics by 5.8% during the first quarter. Schwab Charles Investment Management Inc. now owns 87,057 shares of the biotechnology company’s stock worth $1,892,000 after acquiring an additional 4,788 shares in the last quarter. State Street Corp lifted its position in shares of Aimmune Therapeutics by 49.1% during the first quarter. State Street Corp now owns 858,891 shares of the biotechnology company’s stock worth $18,663,000 after acquiring an additional 282,744 shares in the last quarter. Finally, Credit Suisse AG lifted its position in shares of Aimmune Therapeutics by 14.1% during the first quarter. Credit Suisse AG now owns 42,445 shares of the biotechnology company’s stock worth $924,000 after acquiring an additional 5,248 shares in the last quarter. Hedge funds and other institutional investors own 73.34% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Zacks: Brokerages Anticipate Aimmune Therapeutics, Inc. (AIMT) to Announce -$0.70 EPS” was published by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/12/13/zacks-brokerages-anticipate-aimmune-therapeutics-inc-aimt-to-announce-0-70-eps.html.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Get a free copy of the Zacks research report on Aimmune Therapeutics (AIMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.